Astellas’s $50 Million Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy

Laura Testa
Tagged:

Cooley LLP advised Poseida Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here